Navigation Links
MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy

BOTHELL, WA – June 25 – MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory and infectious diseases, today announced the completion of its confirmatory phase III study of Vascana – a topical formulation designed to treat Raynaud’s Disease.

The study met its primary end point and demonstrated statistical significance, with p = 0.008 for the Intent-to-Treat patient population. Typically, a probability value (p) less than .05 is commonly accepted as establishing statistical significance between treatment groups.

“With the conclusion of this clinical study, MediQuest is one step closer to submitting the Vascana New Drug Application to the FDA,” said MediQuest President and CEO Dr. Frederick Dechow. “If approved, Vascana would be the first drug on the market specifically designed to prevent and treat Raynaud’s symptoms, providing clinicians with a needed treatment for patients.”

Vascana has the potential of satisfying an unmet medical need for more than 2 million Americans seeking care for Raynaud’s Disease.

In addition to Vascana, MediQuest’s ongoing developmental efforts have generated a robust pipeline that includes three drug candidates in clinical trials, one at the pre-clinical stage and others at the research stage. The company develops first- and best-in-class topical therapies to treat patients suffering from inflammatory and infectious diseases.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprietary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company’s major efforts are focused on projects targeting Raynaud’s phenomenon, nail psoriasis and actinic keratosis.

In addition to his
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 2Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 3Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 4Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 5Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010 6Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; New York HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... , ROYAL PALM BEACH, Fla. , Feb. 4 ... (one in three) suffer from some type of cardiovascular disease. Many ... an exciting sports event like the Super Bowl or World Cup ... comparison of death rates from heart attacks in 2002 and 2001, ...
... with natural tissue , THURSDAY, Feb. 4 (HealthDay News) ... in joints has been developed by U.S. researchers. , ... stimulates bone marrow stem cells to produce natural cartilage, ... therapy can do this, according to the researchers, from ...
... , , NORFOLK, Va. , Feb. 4 ... care for the victims of the devastating earthquake in Haiti ... sent three highly skilled medical teams and over 2 1/2 tons ... two days.  The Operation Smile volunteer teams, which are comprised of ...
... N.J. , Feb 4 Smart Balance, Inc. (Nasdaq: ... on February 25, 2010 , at 9:30 a.m. ET ... 8:30 a.m. ET the same day.  The webcast will be ... call by dialing 1-800-895-0198 from the United States or 1-785-424-1053 ...
... ... how it drives social change , ... Morgantown, WV (PRWEB) February 4, 2010 -- Virtual Global, a leading ... SaaS applications, has launched its new portal for cloud computing information, Cloudipedia. The site, ...
... , SACRAMENTO, Calif. , Feb. 4 ... Romans , CEO and Meg Heim, RN , Vice President ... P.A.D. Task Force Committee on behalf of the Governor of ... and the California Department of Chronic Disease and Injury Prevention (CDPH). ...
Cached Medicine News:Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 2Health News:Top 10 Ways to Avoid a Heart Attack This Super Bowl 3Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 2Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 3Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 4Health News:Operation Smile Expands Its Medical Efforts to Help Earthquake Victims in Haiti 5Health News:Smart Balance to Host Webcast/Conference Call on 2009 Fourth-Quarter Results 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 3Health News:BioMedix Vascular Solutions, Inc. Invited to Participate in the California P.A.D. Task Force Committee 2
Single piece PMMA lens, AC depth: 4.9, 2 suture holes....
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
XL STABI Hydrophilic Acrylic Lens....
TRIPODE Hydrophilic Acrylic Lens....
Medicine Products: